

ASX: EIQ RELEASE 14 May 2025

S708A Cleansing Notice

Sydney: All and Medical Technology company Echo IQ ("the Company" or "Echo IQ") (ASX: EIQ) has issued 57,666,667 fully paid ordinary shares (Shares) pursuant to settlement of the placement announced to the market on 7 May 2025, utilising its existing placement capacity under Listing Rule (LR) 7.1A.

The Shares are part of a class of securities quoted on the Australian Securities Exchange Limited (ASX).

The Company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act 2001. The Shares were issued without disclosure to the investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act 2001. The Company, as at the date of this notice, has complied with:

- the provisions of Chapter 2M of the Corporations Act 2001; and
- Section 674 and 674A of the Corporations Act 2001.

There is no excluded information as at the date of this notice, for the purposes of Sections 708A(7) and (8) of the Corporations Act 2001.

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:

Andrew Grover, Executive Chair

<u>Andrew.grover@echoiq.ai</u> / <u>investor@echoiq.ai</u>

Henry Jordan, Six Degrees Investor Relations <u>Henry.jordan@sdir.com.au</u> / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses Al-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

